single molecule barcoding
Veracyte Exclusively Licenses NanoString Diagnostic Platform for up to $60M
Veracyte has also acquired Nanostring's Prosigna breast cancer and LymphMark lymphoma assays and plans to develop diagnostic tests using the nCounter platform.
Veracyte Genomic Classifier Test for Lung Disease Validated in Clinical Study
The study supports the use of Envisia to help with the diagnosis of idiopathic pulmonary fibrosis, particularly in patients without a clear radiological result.
The team plans to eventually implement the MSI test clinically to determine whether patients are eligible for immunotherapy.
The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.